PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14605511-3 2003 Previously, the ADvicor Vs. Other Cholesterol-modulating Agents Trial Evaluation demonstrated that niacin extended release/lovastatin provided greater global improvement in lipid parameters such as low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, lipoprotein (a), apolipoprotein B, and apolipoprotein A-I blood levels compared with atorvastatin and simvastatin monotherapies. Lovastatin 123-133 apolipoprotein B Homo sapiens 305-321 18566298-7 2008 The addition of lovastatin to niacin promoted a lowering in LDL apoB-100 attributable to increased LDL apoB-100 FCR. Lovastatin 16-26 apolipoprotein B Homo sapiens 64-72 18566298-7 2008 The addition of lovastatin to niacin promoted a lowering in LDL apoB-100 attributable to increased LDL apoB-100 FCR. Lovastatin 16-26 apolipoprotein B Homo sapiens 103-111 17319473-15 2006 A fixed dose combination of lovastatin and niacin(ER) significantly improved cholesterol lipoprotein lipids as well as lp(a) and apoA1/apoB levels in Asian Indian dyslipidemic patients. Lovastatin 28-38 apolipoprotein B Homo sapiens 135-139 11144997-5 2001 Statistically significant decreases were also seen for total cholesterol and apolipoprotein B (apo B) with doses of 25 mg to 400 mg of SCH 48461 and lovastatin. Lovastatin 149-159 apolipoprotein B Homo sapiens 77-93 12633795-7 2003 Niacin ER/lovastatin also provided significant improvements in triglycerides, lipoprotein(a), apolipoprotein A-1, apolipoprotein B, and HDL subfractions. Lovastatin 10-20 apolipoprotein B Homo sapiens 114-130 9237640-2 1997 During the 6-week treatment period lovastatin (60 mg/day) decreased fasting serum LDL cholesterol by 45%, LDL phosphorus by 38% and apoB by 33%. Lovastatin 35-45 apolipoprotein B Homo sapiens 132-136 9920144-5 1999 Lovastatin caused a greater decline in total apolipoprotein B (apo B) and LDL apo B than gemfibrozil, whereas VLDL apo B decreased only after gemfibrozil therapy. Lovastatin 0-10 apolipoprotein B Homo sapiens 45-61 9807971-6 1998 After 12 weeks of treatment with lovastatin alone, improvement was observed in total cholesterol (21% reduction), triglyceride (32% reduction), low-density lipoprotein (LDL) cholesterol (5.5% reduction), HDL cholesterol (11.6% elevation), apolipoprotein A-I (4.6% elevation), and apolipoprotein B (20.5% reduction). Lovastatin 33-43 apolipoprotein B Homo sapiens 280-296 9807971-7 1998 The addition of acipimox to lovastatin for an additional 12 weeks further reduced serum total cholesterol, triglyceride, LDL cholesterol, and apolipoprotein B, but this additional decrease was not statistically significant. Lovastatin 28-38 apolipoprotein B Homo sapiens 142-158 9555954-0 1998 Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Lovastatin 21-31 apolipoprotein B Homo sapiens 156-160 9555954-8 1998 The results demonstrate three important outcomes of lovastatin treatment in these subjects: LDL receptor activity increased by 49% (P < 0.02); LDL apoB production rate decreased by 17% (P < 0.03), and LDL particle in vivo affinity for the LDL receptor decreased by 15% (P < 0.01). Lovastatin 52-62 apolipoprotein B Homo sapiens 150-154 9351353-0 1997 Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. Lovastatin 0-10 apolipoprotein B Homo sapiens 59-68 9351353-8 1997 Comparing the kinetic data of these patients with those of 10 normolipidemic control subjects indicates that lovastatin treatment normalized apoB-100 IDL and LDL PR. Lovastatin 109-119 apolipoprotein B Homo sapiens 141-149 9351353-9 1997 The results of these studies suggest that the declines in plasma lipid levels observed after treatment of combined hyperlipidemic patients with lovastatin are attributable to reductions in the C-FSR and C-PR of de novo cholesterol synthesis and the PR of apoB-100 containing lipoproteins. Lovastatin 144-154 apolipoprotein B Homo sapiens 255-263 8935222-14 1996 A significant reduction of serum apolipoprotein B concentrations was also noted in lovastatin period. Lovastatin 83-93 apolipoprotein B Homo sapiens 33-49 9108785-2 1997 This differential effect of lovastatin on apoB-containing lipoprotein families offered the opportunity to determine in the same subset of MARS subjects the independent relationship of LpB and LpBc with the progression of coronary artery disease. Lovastatin 28-38 apolipoprotein B Homo sapiens 42-46 9108785-7 1997 In the placebo- and lovastatin-treated groups combined, progressors had significantly higher on-trial levels of triglycerides (P = .003), VLDL cholesterol (P = .005), apoC-III in VLDL + LDL (P = .008), apoC-III (P = .01), apoB (P = .03), and total cholesterol (P = .04) than nonprogressors. Lovastatin 20-30 apolipoprotein B Homo sapiens 222-226 8628597-10 1996 RESULTS: All lovastatin doses reduced total cholesterol (-17% to -29%), low density lipoprotein cholesterol (-21% to -36%), and ApoB (-19% to -28%) concentrations. Lovastatin 13-23 apolipoprotein B Homo sapiens 128-132 7662319-3 1995 The purpose of the present study was to examine the possible role of cholesterol in regulating apoB secretion by the intestine by testing if the suppression of cholesterol synthesis by the reductase inhibitor lovastatin affected the secretion of apoB by CaCo-2 human intestinal cells. Lovastatin 209-219 apolipoprotein B Homo sapiens 95-99 7662319-3 1995 The purpose of the present study was to examine the possible role of cholesterol in regulating apoB secretion by the intestine by testing if the suppression of cholesterol synthesis by the reductase inhibitor lovastatin affected the secretion of apoB by CaCo-2 human intestinal cells. Lovastatin 209-219 apolipoprotein B Homo sapiens 246-250 8487493-0 1993 The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia. Lovastatin 14-24 apolipoprotein B Homo sapiens 57-73 7981178-0 1994 Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Lovastatin 11-21 apolipoprotein B Homo sapiens 35-39 7981178-2 1994 To establish whether lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, exhibits a specific effect on apolipoprotein (apo) A- and apoB-containing lipoproteins, 63 subjects, a subset of the 270 Monitored Atherosclerosis Regression Study (MARS) patients with hypercholesterolemia (190 to 295 mg/dL) and documented coronary artery disease, were randomized into either lovastatin 40 mg twice daily or matching placebo tablets twice daily. Lovastatin 21-31 apolipoprotein B Homo sapiens 166-170 7706943-11 1995 Lovastatin (20 mg/day) significantly decreased cholesterol (27.6 +/- 6%), LDL-cholesterol (27.6 +/- 9%) and plasma apoB (17.9 +/- 2.9%) (P < 0.01 for all). Lovastatin 0-10 apolipoprotein B Homo sapiens 115-119 7706943-13 1995 Lovastatin significantly decreased LDL-apoB production rate in all cases (34.1 +/- 14%, P = 0.03). Lovastatin 0-10 apolipoprotein B Homo sapiens 39-43 7706943-15 1995 Thus, lovastatin decreased LDL-cholesterol in nephrotic subjects mainly by inhibiting LDL-apoB production from VLDL. Lovastatin 6-16 apolipoprotein B Homo sapiens 90-94 8214993-9 1993 RESULTS: Lovastatin lowered total cholesterol level by 32%, low-density lipoprotein cholesterol by 38%, and the apolipoprotein B by 26% and raised the high-density lipoprotein cholesterol by 8.5% (P < 0.001). Lovastatin 9-19 apolipoprotein B Homo sapiens 112-128 8487493-3 1993 Following 4-6 months of therapy with lovastatin, very low-density lipoprotein apolipoprotein B production in all four subjects had returned to the normal range. Lovastatin 37-47 apolipoprotein B Homo sapiens 78-94 8487493-4 1993 This demonstrates that lovastatin, an inhibitor of cholesterol biosynthesis, acts also to reduce the apparent production rate of apolipoprotein B by the liver. Lovastatin 23-33 apolipoprotein B Homo sapiens 129-145 8399631-3 1993 After 8 weeks of lovastatin treatment, total cholesterol was significantly reduced by 28.6% (6.68 +/- 0.26 mmol/L, mean +/- SEM, to 4.77 +/- 0.12, p < 0.01); low-density lipoprotein cholesterol by 40.5% (4.57 +/- 0.27 mmol/L to 2.72 +/- 0.09, p < 0.01); apolipoprotein B by 32.4% (115.9 +/- 6.99 mg/dL to 78.3 +/- 2.9 mg/dL, p < 0.01); and triglyceride by 17.8% (1.92 +/- 0.38 mmol/L to 1.58 +/- 0.32, p < 0.05). Lovastatin 17-27 apolipoprotein B Homo sapiens 260-276 1395911-5 1992 The results were as follows: Lovastatin reduced significantly the mean serum level of total cholesterol (TC) by 31.5% (P less than 0.001), LDL-C by 39.8% (P less than 0.001), Apo-B by 27.3% (P less than 0.002), and the ratio TC/HDL-C by 35.9% (P less than 0.01). Lovastatin 29-39 apolipoprotein B Homo sapiens 175-180 1302351-6 1992 Significant relationship between apolipoprotein B concentration and dosage of lovastatin was found. Lovastatin 78-88 apolipoprotein B Homo sapiens 33-49 1395911-11 1992 We are, therefore, of the opinion that Lovastatin is an effective agent for lowering the serum level of TC, LDL-C and Apo-B. Lovastatin 39-49 apolipoprotein B Homo sapiens 118-123 1940775-0 1991 Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. Lovastatin 97-107 apolipoprotein B Homo sapiens 65-81 2051734-4 1991 Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day-1) and simvastatin (1st month 10 mg, 2nd month 20 mg and 3rd month 40 mg day-1) reduced total serum cholesterol from 280.3 +/- 9.4 to 213.0 +/- 6.7 (-24%) and 295.0 +/- 12.2 to 202.3 +/- 8.9 mg/dl (-31.4%), LDL cholesterol from 161.9 +/- 10.7 to 112.1 +/- 7.9 (-30.8%) and 181.8 +/- 14.7 to 107.4 +/- 8.1 mg/dl (-40.9%), as well as apolipoprotein B (apo B) from 116.0 +/- 6.6 to 83.3 +/- 3.7 (-28.2%) and 134.4 +/- 8.2 to 84.1 +/- 5.3 mg/dl (-37.4%), respectively. Lovastatin 0-10 apolipoprotein B Homo sapiens 390-406 2810673-4 1989 Lovastatin reduced total and low-density lipoprotein cholesterol and apolipoprotein B levels by 28%, 34%, and 24%, respectively. Lovastatin 0-10 apolipoprotein B Homo sapiens 69-85 2351867-0 1990 Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. Lovastatin 0-10 apolipoprotein B Homo sapiens 51-55 2351867-0 1990 Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. Lovastatin 0-10 apolipoprotein B Homo sapiens 134-138 2351867-0 1990 Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. Lovastatin 0-10 apolipoprotein B Homo sapiens 134-138 2351867-2 1990 Lovastatin therapy significantly reduced plasma levels of LDL cholesterol (142 vs 93 mg/dl, P less than 0.0005) and apoB (1328 vs 797 micrograms/ml, P less than 0.001). Lovastatin 0-10 apolipoprotein B Homo sapiens 116-120 2351867-5 1990 Compared to baseline, treatment with lovastatin was associated with a significant reduction in the total rate of entry of apoB-containing lipoproteins into plasma in all seven CHL subjects (40.7 vs. 25.7 mg/kg.day, P less than 0.003). Lovastatin 37-47 apolipoprotein B Homo sapiens 122-126 2351867-9 1990 In three patients with familial hypercholesterolemia who were studied for comparison, lovastatin treatment increased LDL apoB FCR but did not consistently alter LDL apoB PR. Lovastatin 86-96 apolipoprotein B Homo sapiens 121-125 2351867-10 1990 We conclude that lovastatin lowers LDL cholesterol and apoB concentrations in CHL patients by reducing the rate of entry of apoB-containing lipoproteins into plasma, either as VLDL or as directly secreted LDL. Lovastatin 17-27 apolipoprotein B Homo sapiens 55-59 2351867-10 1990 We conclude that lovastatin lowers LDL cholesterol and apoB concentrations in CHL patients by reducing the rate of entry of apoB-containing lipoproteins into plasma, either as VLDL or as directly secreted LDL. Lovastatin 17-27 apolipoprotein B Homo sapiens 124-128 2294737-5 1990 Lovastatin reduced total cholesterol by 27% from 8.6 +/- 0.6 mmol/L (331 +/- 24 mg/dL) to 6.3 +/- 0.4 mmol/L (242 +/- 17 mg/dL) (P less than 0.01), low-density lipoprotein cholesterol by 27%, from 5.8 +/- 0.5 mmol/L (223 +/- 20 mg/dL) to 4.2 +/- 0.6 mmol/L (163 +/- 22 mg/dL) (P less than 0.01), and apolipoprotein B by 29%, from 153 +/- 12 mg/dL to 109 +/- 8 mg/dL to 109 +/- 8 mg/dL P less than 0.01). Lovastatin 0-10 apolipoprotein B Homo sapiens 300-316 2917701-6 1989 Addition of lovastatin to gemfibrozil effectively reduced total cholesterol (25%), LDL-chol (30%), and LDL-apoB (19%). Lovastatin 12-22 apolipoprotein B Homo sapiens 107-111 3055923-7 1988 Compared with the placebo, lovastatin reduced concentrations of total cholesterol (233 +/- 10 vs 172 +/- 7 mg/dl [standard error of the mean], p less than 0.001), LDL cholesterol (140 +/- 9 vs 101 +/- 6 mg/dl, p less than 0.001), and LDL apolipoprotein-B (108 +/- 16 vs 80 +/- 16 mg/dl, p less than 0.001). Lovastatin 27-37 apolipoprotein B Homo sapiens 238-254 2912427-2 1989 This investigation was carried out in 10 male patients with heterozygous familial hypercholesterolemia to determine the effects of combined drug therapy with lovastatin and colestipol on the kinetics of apolipoprotein B (apo B) in low density lipoproteins (LDL) and very low density lipoproteins (VLDL). Lovastatin 158-168 apolipoprotein B Homo sapiens 203-219 3056429-2 1988 Lovastatin 40 mg bid (twice daily) decreased significantly total serum cholesterol, low density lipoprotein (LDL)-cholesterol, triglycerides and apolipoprotein B by 36%, 45%, 29% and 11%, respectively, while high density lipoprotein (HDL)-cholesterol and apolipoprotein A-I were increased significantly by 16% and 37%, respectively. Lovastatin 0-10 apolipoprotein B Homo sapiens 145-161 3680522-10 1987 Lovastatin reduced both the rate of cholesterol synthesis and the secretion of apoB-containing lipoproteins. Lovastatin 0-10 apolipoprotein B Homo sapiens 79-83 3162680-0 1988 Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Lovastatin 0-10 apolipoprotein B Homo sapiens 78-94 3422105-4 1988 As compared with the placebo, lovastatin reduced total cholesterol by 26 percent, low-density lipoprotein (LDL) cholesterol by 28 percent, and LDL apolipoprotein B by 26 percent. Lovastatin 30-40 apolipoprotein B Homo sapiens 147-163 3680522-0 1987 Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Lovastatin 102-112 apolipoprotein B Homo sapiens 15-31 3113763-7 1987 At 40 mg bid, lovastatin produces the following approximate mean changes: total plasma cholesterol, -33%; low-density lipoprotein (LDL) cholesterol, -40%; very low-density lipoprotein cholesterol, -35%; plasma triglycerides, -25%; high-density lipoprotein cholesterol, +10%; apolipoprotein B, -20%. Lovastatin 14-24 apolipoprotein B Homo sapiens 275-291 3515897-4 1986 Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p less than 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. Lovastatin 163-172 apolipoprotein B Homo sapiens 38-54